For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

Aileron Therapeutics, Inc.

USPTO Granted Patents = 44

CIPO Patents = 4

EPO Patents = 11

Trademarks = 2

Forward Citations = 793

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Huw M Nash (24 out of 35 patents)

Noriyuki Kawahata (19 out of 19 patents)

Vincent Guerlavais (17 out of 22 patents)

4. David Allen Annis (11 out of 13 patents)

5. Tomi K Sawyer (10 out of 35 patents)

6. Eric Feyfant (6 out of 10 patents)

7. Carl Elkin (5 out of 7 patents)

8. Bradford Graves (4 out of 12 patents)

9. Krzysztof Darlak (4 out of 4 patents)

10. Rosana Kapeller-Libermann (4 out of 58 patents)

11. Manuel Aivado (3 out of 3 patents)

12. Karen Olson (3 out of 3 patents)

13. Sameer Ahmed Athamneh (3 out of 3 patents)

14. Manoj Samant (3 out of 3 patents)

15. Christopher Leitheiser (2 out of 3 patents)

Core Competencies:

Peptidomimetic Macrocycles

Disubstituted Amino Acids

Bis-Sulfhydryl Macrocyclization Systems

Triazole Macrocycle Systems

Stabilized P53 Peptides

HIF1alpha Regulation

Therapeutic Macrocycles

Polypeptide Compositions

44 patents: Sort by Forward Citations

1. 11091522 - Peptidomimetic macrocycles and uses thereof (2021-08-17),

2. 11008366 - Peptidomimetic macrocycles (2021-05-18),

3. 10967042 - Peptidomimetic macrocycles (2021-04-06),

4. 10905739 - Peptidomimetic macrocycles and formulations thereof (2021-02-02),

5. 10703780 - Peptidomimetic macrocycles (2020-07-07),

6. 10669230 - Disubstituted amino acids and methods of preparation and use thereof (2020-06-02),

7. 10471120 - Peptidomimetic macrocycles and uses thereof (2019-11-12),

8. 10328117 - Bis-sulfhydryl macrocyclization systems (2019-06-25),

9. 10308699 - Peptidomimetic macrocycles (2019-06-04),

10. 10300109 - Peptidomimetic macrocycles (2019-05-28),

11. 10253067 - Peptidomimetic macrocycles and uses thereof (2019-04-09),

12. 10246491 - Peptidomimetic macrocycles and use thereof in regulating HIF1alpha (2019-04-02),

13. 10227380 - Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles (2019-03-12),

14. 10213477 - Peptidomimetic macrocycles (2019-02-26),

15. 10202431 - Stabilized P53 peptides and uses thereof (2019-02-12),

Aileron Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing and commercializing novel therapeutics for the treatment of cancer. The company's innovative approach involves the use of stapled peptides, a unique class of drugs that have the potential to address previously undruggable disease targets. Aileron Therapeutics is dedicated to improving patient outcomes by advancing the field of peptide therapeutics and bringing transformative treatments to market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

44 Patents

#9 in Watertown, MA

#441 in Massachusetts

#7,670 in US

#15,286 in the World

Watertown, MA, United States of America

Aileron Therapeutics, Inc.

Forward Citations = 793

36 inventors:

Huw M Nash (24 out of 35 patents)

Noriyuki Kawahata (19 out of 19 patents)

Vincent Guerlavais (17 out of 22 patents)

4. David Allen Annis (11 out of 13 patents)

5. Tomi K Sawyer (10 out of 35 patents)

Please report any incorrect information to support@idiyas.com

Loading…